Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost-effectiveness involved with the use of the drug.

Silvestris, N., Vincenzi, B., Brunetti, A.E., Loupakis, F., Dell'Aquila, E., Russo, A., et al. (2014). Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. PHARMACOGENOMICS, 15(13), 1701-1715 [10.2217/pgs.14.124].

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma

Russo, Antonio;Santini, Daniele
2014-01-01

Abstract

Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost-effectiveness involved with the use of the drug.
2014
Silvestris, N., Vincenzi, B., Brunetti, A.E., Loupakis, F., Dell'Aquila, E., Russo, A., et al. (2014). Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. PHARMACOGENOMICS, 15(13), 1701-1715 [10.2217/pgs.14.124].
File in questo prodotto:
File Dimensione Formato  
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.pdf

accesso aperto

Dimensione 6.16 MB
Formato Adobe PDF
6.16 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/295558
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact